Fast Neuroprotection (Fast-NPRX) for Acute Ischemic Stroke Victims: the Time for Treatment Is Now
暂无分享,去创建一个
[1] S. Ricci,et al. Italian guidelines on thrombolysis indications in ischaemic stroke have been revised after IST 3 trial and Cochrane Review: PROS , 2013, Internal and Emergency Medicine.
[2] G. Costantino,et al. Italian guidelines on thrombolysis indications in ischemic stroke have been revised after IST-3 trial and Cochrane revision: cons , 2013, Internal and Emergency Medicine.
[3] Mary G. George,et al. An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.
[4] S. Kasner,et al. Transcranial Laser Therapy and Infarct Volume , 2013, Stroke.
[5] Adrian F Hernandez,et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. , 2013, JAMA.
[6] Eric E. Smith,et al. Prenotification and Other Factors Involved in Rapid tPA Administration , 2013, Current Atherosclerosis Reports.
[7] N. Knuckey,et al. FAST-Mag protocol with or without mild hypothermia (35°C) does not improve outcome after permanent MCAO in rats. , 2013, Magnesium Research.
[8] Arne Voie,et al. Prehospital stroke diagnosis and treatment in ambulances and helicopters-a concept paper. , 2013, The American journal of emergency medicine.
[9] John H. Zhang,et al. Early Brain Injury, an Evolving Frontier in Subarachnoid Hemorrhage Research , 2013, Translational Stroke Research.
[10] P. Lapchak. Recommendations and practices to optimize stroke therapy: developing effective translational research programs. , 2013, Stroke.
[11] D. Boudreau,et al. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. , 2013, Annals of emergency medicine.
[12] Eric E. Smith,et al. Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines–Stroke Hospitals , 2013, Circulation. Cardiovascular quality and outcomes.
[13] P. Hurn,et al. Biological Sex and Mechanisms of Ischemic Brain Injury , 2013, Translational Stroke Research.
[14] N. Alkayed,et al. Mechanism of the Sex Difference in Endothelial Dysfunction after Stroke , 2013, Translational Stroke Research.
[15] D. Liebeskind,et al. Recommendations for Preclinical Research in Hemorrhagic Transformation , 2013, Translational Stroke Research.
[16] M. Stenzel-Poore,et al. Steps to Translate Preconditioning from Basic Research to the Clinic , 2013, Translational Stroke Research.
[17] S. Lazic,et al. A call for transparent reporting to optimize the predictive value of preclinical research , 2012, Nature.
[18] D. J. Cook,et al. A Translational Paradigm for the Preclinical Evaluation of the Stroke Neuroprotectant Tat-NR2B9c in Gyrencephalic Nonhuman Primates , 2012, Science Translational Medicine.
[19] A. Buchan,et al. Neuroprotection for Stroke: Current Status and Future Perspectives , 2012, International journal of molecular sciences.
[20] John H. Zhang,et al. RIGOR Guidelines: Escalating STAIR and STEPS for Effective Translational Research , 2012, Translational Stroke Research.
[21] Susan Thaul,et al. How FDA Approves Drugs and Regulates Their Safety and Effectiveness [May 18, 2012] , 2012 .
[22] S. Doré,et al. Translating Basic Science Research to Clinical Application: Models and Strategies for Intracerebral Hemorrhage , 2012, Front. Neur..
[23] D. J. Cook,et al. Nonhuman Primate Models of Stroke for Translational Neuroprotection Research , 2012, Neurotherapeutics.
[24] G. Donnan,et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. , 2012, The New England journal of medicine.
[25] J. Switzer,et al. Minocycline Prevents IL-6 Increase after Acute Ischemic Stroke , 2012, Translational Stroke Research.
[26] Shao-Hua Yang,et al. Transient Focal Cerebral Ischemia Induces Long-term Cerebral Vasculature Dysfunction in a Rodent Experimental Stroke Model , 2012, Translational Stroke Research.
[27] Thilo Hölscher,et al. Transcranial Ultrasound from Diagnosis to Early Stroke Treatment – Part 2: Prehospital Neurosonography in Patients with Acute Stroke – The Regensburg Stroke Mobile Project , 2012, Cerebrovascular Diseases.
[28] D. Mozaffarian,et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.
[29] E. Peterson,et al. A Qualitative Assessment of Practices Associated With Shorter Door-to-Needle Time for Thrombolytic Therapy in Acute Ischemic Stroke , 2011, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.
[30] Eric E. Smith,et al. Improving Door-to-Needle Times in Acute Ischemic Stroke: The Design and Rationale for the American Heart Association/American Stroke Association's Target Stroke Initiative , 2011, Stroke.
[31] A. C. M. Ercolin,et al. The use of animal models for stroke research: a review. , 2011, Comparative medicine.
[32] P. Lapchak. Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims , 2011, Translational Stroke Research.
[33] A. Ergul,et al. Neurovascular Injury in Acute Hyperglycemia and Diabetes: a Comparative Analysis in Experimental Stroke , 2011, Translational Stroke Research.
[34] D. Hess,et al. Minocycline Development for Acute Ischemic Stroke , 2011, Translational Stroke Research.
[35] Adrian F Hernandez,et al. Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke: Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes , 2011, Circulation.
[36] F. Sharp,et al. Are Underlying Assumptions of Current Animal Models of Human Stroke Correct: from STAIRs to High Hurdles? , 2011, Translational Stroke Research.
[37] D. Mozaffarian,et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.
[38] G. Donnan,et al. History of Animal Models of Stroke , 2011, International Journal of Stroke.
[39] John H. Zhang,et al. Resolving the Negative Data Publication Dilemma in Translational Stroke Research , 2011, Translational Stroke Research.
[40] J. Mckim,et al. CeeTox™ Analysis of CNB-001 a Novel Curcumin-Based Neurotrophic/Neuroprotective Lead Compound to Treat Stroke: Comparison with NXY-059 and Radicut , 2011, Translational Stroke Research.
[41] Sung-Chun Tang,et al. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke , 2011, Molecular Neurodegeneration.
[42] D. Cutler,et al. Trends in thrombolytic use for ischemic stroke in the United States. , 2010, Journal of hospital medicine.
[43] R. Conwit,et al. Intercontinental Elicitation of Informed Consent for Enrollment in Stroke Research , 2010, Cerebrovascular Diseases.
[44] J. Saver,et al. Targeting the Brain: Neuroprotection and Neurorestoration in Ischemic Stroke , 2010, Pharmacotherapy.
[45] Xin Zhao,et al. The “Golden Hour” and Acute Brain Ischemia: Presenting Features and Lytic Therapy in >30 000 Patients Arriving Within 60 Minutes of Stroke Onset , 2010, Stroke.
[46] Muzamil Ahmad,et al. Inflammation After Stroke: Mechanisms and Therapeutic Approaches , 2010, Translational Stroke Research.
[47] R. Vemuganti. The MicroRNAs and Stroke: No Need to be Coded to be Counted , 2010, Translational Stroke Research.
[48] Gregory W Albers,et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.
[49] John H. Zhang,et al. Magnesium Sulfate Treatment Improves Outcome in Patients with Subarachnoid Hemorrhage: A Meta-analysis Study , 2010, Translational Stroke Research.
[50] P. Lapchak. Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development , 2010, Translational Stroke Research.
[51] J. Grotta,et al. Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke: Results of a Prematurely Terminated Randomized Clinical Trial , 2010, Stroke.
[52] J. Mckim. Building a Tiered Approach to In Vitro Predictive Toxicity Screening: A Focus on Assays with In Vivo Relevance , 2010, Combinatorial chemistry & high throughput screening.
[53] Eng H. Lo,et al. The Science of Stroke: Mechanisms in Search of Treatments , 2010, Neuron.
[54] Joanna Wardlaw,et al. Stroke treatment with alteplase given 3·0–4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial , 2009, The Lancet Neurology.
[55] H. Reichmann,et al. Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke , 2009, Stroke.
[56] R. Conwit,et al. Simultaneous Ring Voice-over-Internet Phone System Enables Rapid Physician Elicitation of Explicit Informed Consent in Prehospital Stroke Treatment Trials , 2009, Cerebrovascular Diseases.
[57] R. Bordet,et al. [Cerebral ischaemia: tomorrow's therapeutic tracks]. , 2009, Medecine sciences : M/S.
[58] M. Lansberg,et al. Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke: A Metaanalysis , 2009, Stroke.
[59] B. Dunn,et al. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. , 2009, Stroke.
[60] Marc Fisher,et al. Effectiveness and Safety of Transcranial Laser Therapy for Acute Ischemic Stroke , 2009, Stroke.
[61] J. Attia,et al. Acute ischemic stroke , 2009, Neurology.
[62] S. Savitz. Cosmic Implications of NXY-059 , 2009, Stroke.
[63] E. Lo,et al. The neurovascular unit in health and disease: introduction. , 2009, Stroke.
[64] S. Warach,et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study , 2009, The Lancet Neurology.
[65] D. Mozaffarian,et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.
[66] D. Mozaffarian,et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.
[67] A. Rabinstein. Acute ischemic stroke: Imaging-guided tenecteplase treatment in an extended time window , 2009 .
[68] R. Bordet,et al. [Cerebral ischaemia: tomorrow's therapeutic tracks]. , 2009, Medecine sciences : M/S.
[69] Thilo Hölscher,et al. Transcranial Ultrasound from Diagnosis to Early Stroke Treatment , 2008, Cerebrovascular Diseases.
[70] M. Kaste,et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.
[71] Michael Krams,et al. Missing Steps in the STAIR Case: A Translational Medicine Perspective on the Development of NXY-059 for Treatment of Acute Ischemic Stroke , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[72] Hans-Christoph Diener,et al. NXY-059 for the treatment of acute ischemic stroke. , 2007, The New England journal of medicine.
[73] Marc Fisher,et al. Infrared Laser Therapy for Ischemic Stroke: A New Treatment Strategy: Results of the NeuroThera Effectiveness and Safety Trial–1 (NEST-1) , 2007, Stroke.
[74] J. Biller,et al. Desmoteplase in the treatment of acute ischemic stroke , 2007, Expert review of neurotherapeutics.
[75] J. Koziol. NXY-059 for acute ischemic stroke. , 2006, The New England journal of medicine.
[76] Steven Warach,et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset , 2006, Stroke.
[77] G. Donnan,et al. 1,026 Experimental treatments in acute stroke , 2006, Annals of neurology.
[78] J. Saver. Time Is Brain—Quantified , 2006, Stroke.
[79] A. Rabinstein. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase , 2006 .
[80] Joseph P Broderick,et al. Acute Stroke Care in the US: Results from 4 Pilot Prototypes of the Paul Coverdell National Acute Stroke Registry , 2005, Stroke.
[81] S. Warach,et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase , 2005, Stroke.
[82] P. Gorelick,et al. IMAGES and FAST-MAG: magnesium for acute ischaemic stroke , 2004, The Lancet Neurology.
[83] S. Starkman,et al. Hyperacute treatment initiation in neuroprotective agent stroke trials. , 2004, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[84] Jeffrey L. Saver,et al. Prehospital Neuroprotective Therapy for Acute Stroke: Results of the Field Administration of Stroke Therapy–Magnesium (FAST–MAG) Pilot Trial , 2004, Stroke.
[85] P. Lapchak,et al. Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits , 2004, Experimental Neurology.
[86] M. Meadows. The FDA's drug review process: ensuring drugs are safe and effective. , 2002, FDA consumer.
[87] Meilin Liu,et al. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. , 2013, The Cochrane database of systematic reviews.
[88] Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. , 1999, Stroke.
[89] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[90] Robert C. Wolpert,et al. A Review of the , 1985 .